The main goal of the study is to learn more about how the body absorbs and eliminates Lu AG09222 after a single dose is injected under the skin. Researchers will also investigate safety and tolerability effects of Lu AG09222 after administration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
52
Lu AG09222 will be administered per schedule specified in the arm description.
Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
PAREXEL International
Glendale, California, United States
Area Under the Lu AG09222 Serum Concentration-Time Curve (AUC) From Zero to Infinity (AUC0-inf)
Time frame: Day 1 (predose) to Day 84
Maximum Observed Concentration (Cmax) of Lu AG09222
Time frame: Day 1 (predose) to Day 84
Apparent Elimination Half-Life (t½) of Lu AG09222
Time frame: Day 1 (predose) to Day 84
Time to Maximum Observed Concentration (tmax)
Time frame: Day 1 (predose) to Day 84
Apparent Total Clearance (CL/F)
Time frame: Day 1 (predose) to Day 84
Apparent Volume of Distribution (Vz/F)
Time frame: Day 1 (predose) to Day 84
Number of Participants With Specific Anti-Lu AG09222 Antibodies (Anti-Drug Antibodies [ADA])
Time frame: Day 1 (predose) to Day 84
Number of Participants With Specific ADA-Positive Samples for Neutralizing Antibodies (NAb)
Time frame: Day 1 (predose) to Day 84
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.